SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2013
HYDROMER , INC.
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
35 Industrial Parkway, Branchburg N.J. 08876
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
Press Release Announcing Hydromer, Inc. Entering Into an Exclusive License Agreement with Ortopro AS for Implantable Orthopedic Devices
Press Release Issued March 7, 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 8, 2013
/s/ Robert Y. Lee
Name: Robert Y. Lee
Title: Chief Financial Officer
Hydromer Enters Into a Exclusive License Agreement with Ortopro AS for Implantable Orthopedic Devices
Branchburg, March 07, 2013 --- Hydromer, Inc. (HYDI.PK) announced that it entered into a royalty bearing Exclusive License Agreement with Ortopro AS (Ortopro) of Turkey.
Under the terms of this agreement, OrtoPro is licensed to use proprietary Hydromer® biofilm resistant coatings on various implantable orthopedic devices, such as bone screws. Test data has indicated that the licensed Hydromer coating formulation aids in reducing the infection risk of such implants. Ortopro has agreed to conduct additional biological and biocompatibility studies hopefully leading to regulatory approval in the Exclusive Territory of Turkey.
“We are tremendously proud and honored with our new relationship, which will help propel Hydromer’s entry into the lucrative orthopedic implant market”, commented Martin von Dyck, Executive Vice President of Hydromer, Inc., adding, “Hydromer and Ortopro have been working closely together in addressing the vexing problem of infections associated with orthopedic implants which are very difficult to resolve using conventional intravenous antibiotic therapy. In fact, often an infected implant must be removed or treated via another surgical procedure. It is our belief that the new Hydromer formula will mitigate this infection risk”
About Hydromer, Inc.: Hydromer, Inc. is a bio-technology-based company involved in the research and development, manufacture, contract coating and commercialization of specialized polymer and hydrogel products for medical device, animal health, cosmetic, personal care, and industrial uses. These technologies include Hydromer lubricious / anti-microbial / anti-thrombogenic / cell anti-mitosis / cell growth enhancing coatings for the medical marketplace.
For additional information please visit the following Web-site: www.hydromer.com
Hydromer® is a registered trademark of Hydromer, Inc.